ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$4.34 USD
-0.10 (-2.25%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.34 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
ADC Therapeutics SA (ADCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.62 | $13.00 | $0.70 | 94.14% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for ADC Therapeutics SA comes to $8.62. The forecasts range from a low of $0.70 to a high of $13.00. The average price target represents an increase of 94.14% from the last closing price of $4.44.
Analyst Price Targets (6 )
Broker Rating
ADC Therapeutics SA currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.86 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 57.14% and 14.29% of all recommendations. A month ago, Strong Buy made up 57.14%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 1.86 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Strong Buy |
3/28/2024 | Guggenheim Securities | Michael Schmidt | Not Available | Strong Buy |
3/6/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $8.62 |
LT Growth Rate | 41.90% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.58 |